CA-LASERFICHE
15.5.2024 16:01:35 CEST | Business Wire | Press release
Laserfiche — the leading SaaS provider of intelligent content management and business process automation — announced today that CRN®, a brand of The Channel Company, has named Noel Loughrin, Katherine Hou, and Kristen Petruzzelli to the Women of the Channel list for 2024.
These channel leaders are an instrumental part of Laserfiche’s success, which includes growing the Laserfiche channel’s footprint and expertise in various industries. Loughrin, Hou, and Petruzzelli are committed to providing the resources and support that enable solution providers to drive digital transformation at organizations around the world.
As senior strategic solutions manager for the public sector, Loughrin is a passionate technologist and Laserfiche advocate. Loughrin works with organizations in local, state, and federal governments, as well as education, to bring about transformative change for constituents, students, and staff. She puts her public sector expertise at the service of Laserfiche channel partners by fostering strategic technology partnerships and championing integrations that build awareness, generate opportunities, and encourage customer retention.
Hou is a territory manager and trusted resource and advocate for Laserfiche channel partners. She focuses on strategic campaigns that empower partners and amplify the Laserfiche brand. Hou is committed to building awareness at industry events, cultivating trust between Laserfiche and its channel partners, and serving as a reliable resource during rapidly changing socio-economic conditions.
As senior customer success manager, Petruzzelli is dedicated to elevating the level of Laserfiche customer service and streamlining operational processes. She recently optimized service standards by spearheading new policies and procedures to save time for customers and solution providers, as well as increase customer satisfaction.
Every year, CRN highlights women from vendor, distributor, and solution provider organizations whose vision and leadership have a beneficial influence on the technology industry. The CRN 2024 Women of the Channel honorees are creative, strategic leaders who show ongoing commitment to using their skills to innovate and drive success for their partners and customers.
With this recognition, CRN honors these women leaders for their unwavering dedication and commitment to furthering channel excellence.
“It is a great privilege to honor the remarkable achievements of these women leaders in the IT channel,” said Jennifer Follett, VP, U.S. Content and Executive Editor, CRN at The Channel Company. “Each woman on the list has demonstrated a deep commitment to innovation and leadership that advances their organizations and drives transformation and success across the IT channel.”
“In the past year these leaders have worked purposefully in not only growing our channel presence but also in empowering resellers, creating a customer-centric partner ecosystem that encourages and enables our solution providers to grow with Laserfiche,” said Vicki VanValin, vice president of sales at Laserfiche. “This recognition from CRN underscores our dedication to the Laserfiche Solution Provider Program, which is essential to Laserfiche's growth and delivering on our vision.”
The 2024 Women of the Channel list will be featured in the June issue of CRN Magazine, with online coverage starting May 13 at www.CRN.com/WOTC.
About Laserfiche
Laserfiche is the leading SaaS provider of intelligent content management and business process automation. Through powerful workflows, electronic forms, document management, and analytics, the Laserfiche® platform accelerates how business gets done, enabling leaders to focus on growth across the enterprise.
Laserfiche pioneered the paperless office with enterprise content management. Today, Laserfiche’s cloud-first development approach incorporates innovations in machine learning and AI to enable organizations in more than 80 countries to transform into digital businesses. Customers in every industry — including government, education, financial services, healthcare, and manufacturing — use Laserfiche to boost productivity, scale their business, and deliver digital-first customer experiences.
Laserfiche employees in offices around the world are committed to the company’s vision of empowering customers and inspiring people to reimagine how technology can transform lives.
Connect with Laserfiche:
Laserfiche Blog | Twitter | LinkedIn | Facebook
About The Channel Company
The Channel Company enables breakthrough IT channel performance with our dominant media, engaging events, expert consulting and education, and innovative marketing services and platforms. As the channel catalyst, we connect and empower technology suppliers, solution providers, and end-users. Backed by over 40 years of unequaled channel experience, we draw from our deep knowledge to envision innovative solutions for ever-evolving challenges in the technology marketplace. www.thechannelcompany.com
Follow The Channel Company: X and LinkedIn
© 2024. CRN is a registered trademark of The Channel Company, Inc. All rights reserved.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240515678202/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
